Biological and genetic markers of sporadic Alzheimer's disease

Acta Medica Okayama

Volumn 55, Issue 2, 2001, Pages 55-63

  Engelborghs, Sebastiaan ^a   De Deyn, Peter Paul ^a  

^a NONE

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Dementia; Marker; Neurochemistry

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CYTOKINE; NEUROPEPTIDE; PEPTIDE FRAGMENT; SUPEROXIDE DISMUTASE; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; GENETIC MARKER; GENETICS; HUMAN; METABOLISM; REVIEW;

ALZHEIMER DISEASE; AMINO ACIDS; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CYTOKINES; GENETIC MARKERS; HUMANS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; PEPTIDE FRAGMENTS; SUPEROXIDE DISMUTASE; TAU PROTEINS;

EID: 0035318506     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. De Deyn PP, Goeman J, De Smedt C, Mulleners E, Engelborghs S and Pickut BA: Actuele geneesmiddelen in de behandeling van dementie van het Alzheimer-type. Tijdschrift voor Geneeskunde (2000) 56, 582-589 (in Dutch).
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology (1984) 34, 939-944.
3. Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B and Blennow K: Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology (1999) 53, 1488-1494.
4. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group: Consensus Report of the Working Group on Molecular and Biochemical Markers for Alzheimer's disease. Neurobiol Aging (1998) 19, 109-116.
5. Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, Seiki H, Takase S, Clark CM, Lee VM, Trojanowski JQ and Sasaki H: Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer' s disease. Ann Neurol (1995) 38, 649-652.
6. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, Raiha I, Sourander L, Winblad B and Blennow K: Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer' s disease: A community based follow up study. J Neurol Neurosurg Psychiatry (1998) 64, 298-305.
7. Skoog I, Vanmechelen E, Andreasson LA, Palmertz B, Davidsson P, Hesse C and Blennow K: A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration (1995) 4, 433-442.
8. Galasko D, Motter R and Seubert P: Interpreting cerebrospinal fluid tau levels in Alzheimer's disease. Neurobiol Aging (1996) 17, S1.
9. Molina L, Touchon J, Lefranc D, Vermersch P, Pau B and Mourton-Gilles C: Detection of tau proteins in cerebrospinal fluids from Alzheimer's patients. Neurobiol Aging (1996) 17, S166.
10. Zapotoczky HG: Problems of differential diagnosis between depressive pseudodeomentia and Alzheimer's disease; in Ageing and dementia, Jellinger K, Fazekas F and Winsdisch M eds, Springer Verlag, New York (1998) pp 91-95.
11. Burger nee Buch K, Padberg F, Nolde T, Teipel SJ, Stubner S, Haslinger A, Schwarz MJ, Sunderland T, Arai H, Rapoport SI, Möller H-J and Hampel H: Cerebrospinal fluid tau protein shows a better discrimination in young old (< 70 years) than in old old patients with Alzheimer's disease compared with controls. Neurosci Lett (1999) 277, 21-24.
12. Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park J-M, Sato K, Kohno H and Imahori K: Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett (1999) 270, 91-94.
13. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N and Ihara Y: Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron (1994) 13, 45-53.
14. (1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 56, 673-680.
15. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Seubert P and Schenk D: Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 38, 643-648.
16. Nakamura T, Shoji M, Harigaya Y, Watanabe M, Hosoda K, Cheung TT, Shatter LM, Golde TE, Younkin LH, Younkin SG and Hirai S: Amyloid β-protein level in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol, (1994) 36, 903-911.
17. Engelborghs S and De Deyn PP: The neurochemistry of Alzheimer's disease. Acta Neurol Belg (1997) 97, 67-84.
18. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT and Delon MR: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science (1982) 215, 1237-1239.
19. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P and Davis KL: Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits. J Neurochem (1995) 64, 749-760.
20. Tohgi H, Abe T, Hashiguchi K, Saheki M and Takahashi S: Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett (1994) 177, 139-142.
21. Davis KL, Hsieh JY, Levy Ml, Horvath TB, Davis BM and Mohs RC: Cerebrospinal fluid acetylcholine, choline and senile dementia of the Alzheimer's type. Psychopharmacol Bull (1982) 18, 193-195.
22. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G and Haroutunian V: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA (1999) 281, 1401-1406.
23. Navaratnam DS, Priddle JD, McDonald B, Esiri MM, Robinson JR and Smith AD: Anomalous molecular form of acetylcholinesterase in cerebrospinal fluid in histologically diagnosed Alzheimer's disease. Lancet (1991) 337, 447-450.
24. Shen ZX: An CSF anomalous molecular form of acetylcholinesterase in demented and non-demented subjects. Neuroreport (1997) 8, 3229-3232,
25. Saez-Valero J, Sberna G, McLean CA and Small DH: Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J Neurochem (1999) 72, 1600-1608.
26. Bondareff W, Mountjoy CQ, Roth M, Rossor MN, Iversen LL and Reynolds GP: Age and histopathologic heterogeneity in Alzheimer's disease. Evidence for subtypes. Arch Gen Psychiatry (1987) 44, 412-417.
27. Mann DM, Yates PO and Marcyniuk B: A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1984) 47, 201-203.
28. Martignoni E, Blandini F, Petraglia F, Pacchetti C, Bono G and Nappi G: Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect (1992) 4, 191-205.
29. Raskind MA, Peskind ER, Halter JB and Jimerson DC: Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch Gen Psychiatry (1984) 41, 343-346.
30. Hollander E, Mohs RC and Davis KL: Antemortem markers of Alzheimer's disease. Neurobiol Aging (1986) 7, 367-407.
31. Herregodts P, Michotte Y and Ebinger G: Regional differences in the distribution of norepinephrine and epinephrine in human cerebral cortex: A neurochemical study using HPLC and electrochemical detection. Neurosci Lett (1989) 98, 321-326.
32. Herregodts P, Bruyland M, De Keyser J, Solheid C, Michotte Y and Ebinger G: Monoaminergic neurotransmitters in Alzheimer's disease. An HPLC study comparing familial and sporadic senile cases. J Neurol Sci (1989) 92, 101-116.
33. Tohgi H, Takahashi S and Abe T: The effect of age on concentration of monoamines, amino acids, and their related substances in the cerebrospinal fluid. J Neural Transm Park Dis Dement Sect (1993) 5, 215-226.
34. Arai H, Kosaka K and Iizuka R: Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem (1984) 43, 388-393.
35. Allard PO, Rinne J and Marcusson JO: Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type. Brain Res (1994) 637, 262-266.
36. Nakashima S and Ikuta F: Catecholamine neurons with Alzheimer's neurofibrillary changes and alteration of tyrosine hydroxylase. Immunohistochemical investigation of tyrosine hydroxylase. Acta Neuropathol (1985) 66, 37-41.
37. Mann DM, Lincoln J, Yates PO, Stamp JE and Toper S: Changes in the monoamine containing neurons of the human CNS in senile dementia. Br J Psychiatry (1980) 136, 533-541.
38. Volicer L, Direnfeld LK, Langlais PJ, Freedman M, Bird ED and Albert ML: Catecholamine metabolites and cyclic nucleotides in cerebrospinal fluid in dementia of Alzheimer type. J Gerontol (1985) 40, 708-713.
39. Curcio CA and Kemper T: Nucleus raphe dorsalis in dementia of the Alzheimer type: Neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol (1984) 43, 359-368.
40. Tohgi H, Abe T, Takahashi S, Kimura M, Takahashi J and Kikuchi T: Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci Lett (1992) 141, 9-12.
41. Vandenabeele P and Fiers W: Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated "acute phase response" in the brain? Immunol Today (1991) 12, 217-219.
42. Mrak RE, Sheng JG and Griffin WS: Glial cytokines in Alzheimer's disease: Review and pathogenic implications. Hum Pathol (1995) 26, 816-823.
43. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL IIIrd and Araoz C: Brain interleukin I and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA (1989) 86, 7611-7615.
44. Griffin WS, Sheng JG, Roberts GW and Mrak RE: Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J Neuropathol Exp Neurol (1995) 54, 276-281.
45. Sheng JG, Mrak RE and Griffin WS: Microglinal interleukin-1α expression in brain regions in Alzheimer's disease: Correlation with neuritic plaque distribution. Neuropathol Appl Neurobiol (1995) 21, 290-301.
46. Huell M, Strauss S, Volk B, Berger M and Bauer J: Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol (1995) 89, 544-551.
47. Breitner JC: Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal. Neurobiol Aging (1996) 17, 789-794.
48. Engelborghs S, De Brabander M, De Cree J, D'Hooge R, Geerts H, Verhaegen H, De Deyn PP: Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochemistry Int (1999) 34, 523-530.
49. De Deyn PP, Hiramatsu M, Borggreve F, Goeman J, D'Hooge R, Saerens J, Mori A: Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. Alzheimer Dis Assoc Disord (1998) 12, 26-32.
50. Jenner P: Oxidative damage in neurodegenerative disease. Lancet (1994) 344, 796-798.
51. Perrin R, Briancon S, Jeandel C, Artur Y, Minn A Penin F and Siest G: Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: A case-control study. Gerontology (1990) 36, 306-313.
52. de Lustig ES, Serra JA, Kohan S, Canziani GA, Famulari AL and Dominguez RO: Copper-zinc superoxide dismutase activity in red blood cells and serum in demented patients and in aging. J Neurol Sci (1993) 115, 18-25.
53. Zemlan FP, Thienhaus OJ and Bosmann HB: Superoxide dismutase activity in Alzheimer's disease: Possible mechanism for paired helical filament formation. Brain Res (1989) 476, 160-162.
54. Bracco F, Scarpa M, Rigo A and Battistin L: Determination of superoxide dismutase activity by the polarographic method of catalytic currents in the cerebrospinal fluid of aging brain and neurologic degenerative diseases. Proc Soc Exp Biol Med (1991) 196, 36-41.
55. Hiramatsu M, Kohno M, Edamatsu R, Mitsuta K and Mori A: Increased superoxide dismutase activity in aged human cerebrospinal fluid and rat brain determined by electron spin resonance spectrometry using the spin trap method. J Neurochem (1992) 58, 1160-1164.
56. Degrell I, Hellsing K, Nagy E and Niklasson F: Amino acid concentrations in cerebrospinal fluid in presenile and senile dementia of Alzheimer type and multi-infarct dementia. Arch Gerontol Geriatr (1989) 9, 123-135.
57. Martinez M, Frank A, Diez-Tejedor E and Hermanz A: Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. J Neural Transm Park Dis Dement Sect (1993) 6, 1-9.
58. Zimmer R, Teelken AW, Trieling WB, Weber W, Weihmayr T and Lauter H: γ-Aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer's type. Arch Neurol (1984) 41, 602-604.
59. Bissette G and Myers B: Somatostatin in Alzheimer's disease and depression. Life Sci (1992) 51, 1389-1410.
60. Beal MF, Growdon JH, Mazurek MF and Martin JB: CSF somatostatin-like immunoreactivity in dementia. Neurology (1986) 36, 294-297.
61. Davies CA, Moroll DR, Prinja D, Mann DM and Gibbs A: A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J Neurol Sci (1990) 96, 59-73.
62. Edvinsson L, Minthon L, Ekman R and Gustafson L: Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia (1993) 4, 167-171.
63. St George-Hyslop PH: Molecular genetics of Alzheimer's disease. Biol Psychiatry (2000) 47, 183-199.
64. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Locascio JJ, Perls TT, Lipsitz LA and Hyman BT: Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease. Ann Neurol (1996) 39, 62-70.
65. Growdon JH: Biomarkers of Alzheimer disease. Arch Neurol (1999) 56, 281-283.
66. Wisniewski T and Frangione B: Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett (1992) 135, 235-238.
67. Scacchi R, Gambina G, Ruggeri M, Martini MC, Ferrari G, Silvestri M, Schiavon R and Corbo RM: Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci Lett (1999) 259, 33-36.
68. de la Monte SM and Wands JR: Neuronal thread protein over-expression in brains with Alzheimer's disease lesions. J Neurol Sci (1992) 113, 152-164.
69. de la Monte SM, Volicer L, Hauser SL and Wands JR: Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1992) 32, 733-742.
70. Blennow K and Vanmechelen E: Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J Neural Transm (1998) 53, 223-235.
71. (1-42) and tau levels in CSF. Neurology (1999) 52, 1555-1562.